ArticleOncology letters2021
Expression level of E-, N- and P-cadherin proteins in endometrial cancer.
Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Article
- Article
- Expression of E-Cadherin and N-Cadherin in the Endocervix as a Predictive Factor in Patients with Endometrial Cancer.International journal of molecular sciences · 2024Article
- The association of Wnt-signalling and EMT markers with clinical characteristics in women with endometrial cancer.Frontiers in oncology · 2023Article
- Research Progress of DNA Methylation in Endometrial Cancer.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to examine the protein expression levels of E-, N- and P-cadherin, which are involved in the proliferation of neoplastic cells, in cancer tissue from patients with endometrial cancer. Furthermore, the present study aimed to investigate the effect of these proteins on clinicopathological parameters. Immunohistochemistry was performed to detect the protein expression levels of the aforementioned cadherins in 38 primary endometrial tumors, 20 metastatic tumors (nine metastases to the lymph nodes and 11 distant metastases) and five cases of atypical hyperplasia as the control group. It was found that the E-, N- and P-cadherin proteins in hyperplastic endometrial lesions with atypia were weakly expressed in the cytoplasm, while the expression levels of E-, N- and P-cadherin proteins, in endometrial cancer tissue, were located in the membrane and/or in the cytoplasm, and was found to be unevenly distributed. Furthermore, increased expressed level of the three cadherin proteins was observed at the tumor front, as opposed to in the main mass, of endometrial cancer tumor. It was demonstrated that membrane expression levels of the 3 cadherin proteins were lower in metastatic cancer cells compared with that in the primary tumor cells. In addition, a significantly higher cytoplasmic expression level of E-cadherin and increased membranous and cytoplasmic expression of P-cadherin, were associated with high-grade tumor budding. Furthermore, a higher percentage of P-cadherin membrane expression level was associated with poorly differentiated cancer cell types. The present results suggested that the increased membrane expression level of E-cadherin was associated with the presence of local lymph node involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.